Form 4: UTHR CEO Executes Pre-Arranged Stock Option Sales
Insider Transaction Report
United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed pre-arranged sales of common stock totaling 8,000 shares from option exercises on October 7 and 8, 2025, under a 10b5-1 trading plan.
Summary
- Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving common stock.
- On October 7, 2025, Rothblatt exercised 4,000 stock options at $120.26 per share and subsequently sold 4,000 shares at weighted average prices ranging from $450.31 to $453.28.
- On October 8, 2025, Rothblatt exercised another 4,000 stock options at $120.26 per share and sold 4,000 shares at weighted average prices ranging from $445.289 to $456.52.
- These transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
- The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
- Following these transactions, Rothblatt directly holds 130 shares of common stock.
- Indirect holdings include 166 shares by spouse and 644,193 shares across various family trusts.
- Remaining derivative securities (stock options) beneficially owned after these transactions are 198,000.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions under a pre-arranged 10b5-1 plan, which is a neutral event. The executive is monetizing vested equity, which is a positive for the individual, but the sale itself is a neutral event for the company's outlook.
Positives
- The executive is monetizing vested equity, indicating a realization of value from their compensation.
- Transactions were conducted under a pre-arranged 10b5-1 trading plan, which enhances transparency and mitigates concerns about insider trading.
- The sale prices significantly exceed the exercise price of $120.26, reflecting substantial gains on the exercised options.
Negatives
- Executive share sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though these are routine for compensation.
Risks
- No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing. The filing is solely about insider transactions.
Future Outlook
The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
Industry Context
This Form 4 filing details routine insider transactions by a senior executive and does not provide information relevant to broader industry trends or competitive landscape analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Implementation | The reporting person entered into a pre-arranged 10b5-1 trading plan on May 2, 2025, to manage the sale of equity securities, ensuring compliance with insider trading regulations. | 05/02/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations by pre-scheduling transactions. |
Related Party Transactions
- Shares held indirectly in various family trusts where the Reporting Person and/or immediate family members are beneficiaries or have investment power.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive stock transactions, which are routine for compensation and wealth management. The pre-arranged nature mitigates concerns about opportunistic selling.
- Employees: No direct impact on employees.
- Customers/Suppliers/Creditors: No direct impact on these stakeholders.
Next Steps
- Continuation of the pre-arranged 10b5-1 trading plan for further stock option exercises and sales.
Key Dates
| Date | Description |
|---|---|
| 03/15/2016 | Stock options became exercisable. |
| 05/02/2025 | Pre-arranged 10b5-1 trading plan was entered into by the reporting person. |
| 10/07/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 10/08/2025 | Date of stock option exercise and subsequent sale of common stock, and signature date of the filing. |
| 12/31/2025 | Earlier of two dates for the termination of the 10b5-1 trading plan. |
| 03/15/2026 | Expiration date of the tranche of 294,000 stock options covered by the 10b5-1 plan. |
Keywords
United Therapeutics, UTHR, Martine Rothblatt, SEC Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.